获得更多客户是结果。决策在于选择哪条路线能在重复时保持利用率和实现率。 专业服务公司在此有特定困境——合伙人薪酬理性地支付人们<em>不</em>去销售公司最高利润率的产品。在这个问题定价前，可计费利用率会持续移动，原因无人能归因，而关于渠道CAC的争论将停留在意见层面。
获得更多客户是结果。决策在于选择哪条路线能在重复时保持利用率和实现率。 专业服务公司在此有特定困境——合伙人薪酬理性地支付人们不去销售公司最高利润率的产品。在这个问题定价前，可计费利用率会持续移动，原因无人能归因，而关于渠道CAC的争论将停留在意见层面。
几乎每家公司都能说出几种赢得业务的方法，但很少能说出哪一种能提高每合伙人收入或项目毛利率。这才是实际约束：不是路线短缺，而是没有证据表明哪条路线在规模化时能提升这些指标。
有效的框架是路线经济学。对每条可行路线——合伙人主导的拓展、转介计划、联盟、搜索凭证、活动或分包——它对可计费利用率有何影响，多久能让项目利润覆盖从收费工作中转移的时间，以及路线能否在量增时不降低实现率地重复。
多数路线过不了第三项测试。它们产生早期业务，是因为利用了管理合伙人的现有关系或个人时间，当合伙人薪酬结构把注意力拉回自身账本的可计费利用率时，这些路线便悄然停止。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 利用率和实现率仅以汇总形式报告，而单个合伙人报告非计费时间上升。
✓ 项目利润率和每合伙人收入无法追溯到管道中的任何单一路线。
✓ 每条路线每月都获得一些合伙人小时，但没有一条获得足够连续周数来显示它是否移动了待命或实现率。
通常会让情况更糟的做法。 同时以部分利用率运行多条路线，这让每位合伙人的时间被分割，在任何路线上都未产生每合伙人收入或项目利润率的决定性移动，并使整体待命高于全力测试一条路线的水平。
It is for you if you run or finance a professional services firm and growth depends on one person's relationships. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家专业服务公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Aldergate Partners, a sample company profile used for testing rather than a customer — $88M revenue, 310 people.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Re-align partner economics so the diagnostic that already converts 63% of the time becomes the default first sale.
| Investment required | $0.9–1.1M total over 12 months: $0.4M for partner-success function (3 FTE), $0.3M for vertical-IP playbook development (4 FTE from existing bench), $0.2M for compensation-model simulation. |
| Expected return | Incremental EBITDA of $2.4–3.2M annually once 40 diagnostics/year achieved; payback period 4–6 months after compensation redesign goes live. |
| Revenue, year 1 | $60.5–62.0M (base case assumes 28 diagnostics sold, 65% attach rate) |
| Revenue, year 2 | $66–69M (40 diagnostics, 70% attach rate, vertical-IP packages live) |
| Revenue, year 3 | $74–78M (52 diagnostics, 75% attach rate, UK/EU regulatory playbooks optional) |
| Exit criteria | Strategy should be reversed if, within 12 months, (a) diagnostic attach rate falls below 45% for two consecutive quarters, OR (b) ≥4 partners depart (18% attrition), OR (c) partner cash-impact delta is negative for ≥50% of partners for two consecutive quarters. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For 专业服务公司 it works through billable utilisation, realisation, revenue per partner and engagement gross margin, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
买家已经在的、且能在你能融资的周期内收回获客成本的渠道。这是业务特定的，通用答案价值很小。
先运行一个有效的，然后再加第二个。以必要预算的四分之一运行四个， reliably 产生四个无结论的结果，并让人相信什么都不起作用。
你的销售周期加上一个回本期，加上足够区分结果与噪声的量。提前设定这个数字，能防止决策被最有说服力的人左右。
Materially, yes. Partner compensation rationally pays people not to sell the highest-margin product in the firm — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are billable utilisation, realisation, revenue per partner, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on billable utilisation and realisation. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית